NCBiR Patent Plus Posted on 26 February 201921 March 2019 by Paulina Czarnecka The aim of the program is to subsidize the activities of scientific entities and entrepreneurs for applying for a European and international patent protection for acquired by them as the results of research or development. SDS Optic was granted by National Centre of Research and Development in Patent Plus programme.
Horizon 2020 SME Instrument Posted on 26 February 20194 April 2019 by Paulina Czarnecka The European Commission has contributed to SDS Optic’s project “Revolutionary opto-biological methodology for aggressive HER2 cancer”. The startup from Lublin was granted €3.985.000 from the SME Instrument (Horizon 2020) programme to develop a revolutionary optical device OmiProbe for safe, fast and non-destructive cancer diagnosis. As part of the Horizon 2020 programme, the European Commission is hand-picking potentially disruptive businesses to invest and support as part of the SME Instrument. In the latest phase (June 2017), 1514 projects applied for the financial support and only 57 (2 from Poland) got funding. The grant for SDS Optic is so far the largest for the polish company and also the largest in this phase of the programme. It will finance optimisation of the SDS-OmiProbe device, independent clinical trials, certification and commercialisation. SDS Optic designed a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS inProbe detects presence and measures concentration levels of the HER+ cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs. According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease. Current diagnosis methods of cancers fail to deliver objective results. Diagnosis requires extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which is subject to significant levels of discordance. Thanks to SDS-OmiProbe, the accurate result of the same analysis will be achievable in a few minutes. It will spare the patient’s pain and stress connected with biopsy and waiting for the results. It is planned that the first patients will be diagnosed using SDS inProbe in 2021. Visit official website: https://ec.europa.eu/programmes/horizon2020/en
Our vision Posted on 18 February 20197 October 2022 by Paulina Czarnecka Increasing the survival rate of cancer patients by 30% by 2030 SDS Optic S.A. creates and develops diagnostic and monitoring solutions, combining optoelectronics (photonics) with molecular biology, medical bioengineering and immunochemistry. The mission of SDS Optic S.A. is one of the main objectives that many countries and international organizations have committed themselves to achieving. On 4 February 2017, on World Cancer Day, the World Health Organization published a new list of recommended medical procedures and services, that are required at an early stage of cancer development, to increase the chances of curing the patients. According to the WHO, it is necessary to intensify the global development of diagnostic solutions that can be applied at the very beginning of the diagnostic pathway for people with suspected cancer. Many countries have committed themselves to the Sustainable Development Goals (SDGs). One of the points of this agenda is to reduce premature deaths caused by cancer by 1/3 by 2030. Our mission and objectiveis to increase the survivalof cancer patientsby 30% by 2030. WHO is not the only international institution that, like SDS Optic, wishes to fight for the life of cancer patients. The objective of improving the quality of life and extending the life expectancy of 3 million people by 2030 through prevention and treatment, and supporting cancer patients and their families, was also included in the European Commission’s Horizon Europe document. SDS Optic S.A. consciously the mission of increasing cancer survival by 30% by 2030 in its DNA. Research, reports and the direction of development of global and renowned organizations indicate that effective solutions for the diagnosis of diseases at the earliest possible stage can save human life and health. That’s why we created inPROBE – a micron optical biosensor for the detection of bioelements in real time, in vivo (inside the human body). You can find more on how our technology works at https://inprobe.com/.
LSX World Congress London 2019 Posted on 6 February 20194 April 2019 by Paulina Czarnecka The 6th annual LSX World Congress was a high-calibre, senior executive, two-day conference, exhibition and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses. Event took part in London where 750 top life science executives meet each other to discuss future of life science investment market. Days were full of one-2-one meetings planned, Innovation Zone hosted by #MSD, IPO Bootcamp hosted by Nasdaq, CEO Forum, Startup CEO Forum. Many great investors were here so it was very busy day for Mateusz Sagan, our Chief Business Officer and Supervisory Board Member.
Arab Health 2019 – biggest healthcare event in the world Posted on 29 January 20193 April 2019 by Paulina Czarnecka Arab Health 2019 was a great way to present our HER2 breast cancer diagnostics microsonde. Undoubtedlly it’s the largest medical exhibition and conference in the Middle East and one of the biggest healthcare event in the world. These days were very busy for whole SDS Optic team but we were happy to to meet so many people from so many countries and told them more about inPROBE new technology.
Bio Europe Posted on 27 November 20183 April 2019 by Paulina Czarnecka We were in Copenhagen at BIOEurope which is Europe’s largest partnering conference serving the global biotechnology industry. It was great networking event and great oppportunity to present our inPROBE at PolishBiotechHub organized and funded by Polska Agencja Inwestycji i Handlu – PAIH. Great for us to were there together with excellent entourage like OncoArendi Therapeutics SA NanoVelos NanoSanguis, Inc. Ardigen Pure Biologics and Selvita
SDS at Medica Trade Fair Posted on 20 November 20183 April 2019 by Paulina Czarnecka Our team were present at Medica Trade Fair 2018 – World Forum for Medicine. We had a great 4 days for our inPROBE Smart Cancer Diagnostics technology, hundreds of talks and pitching all the time in front of people from Brazil, India, Japan, Germany, USA and many many others. A great support of our Lublin Medical Cluster Klaster Lubelska Medycyna and personal support of its Head Marzena Strok-Sadło. We thank everyone who supports our disruptive cancer biomarkers innovation, who visited us and had a talk with us and see you at next year edition of Medica.
SITC 2018 Posted on 11 November 20184 April 2019 by Paulina Czarnecka We were at SITC 2018 conference, the most important event in Immunotherapy area. Thousands of scientists and oncologists and biggest pharma discussed the future of Immunotherapies & importance of new breakhrough diagnostics approach. Thanks to our American partner we had a privilage to be invited to this event and our Chief Science Officer took part in that important discussions.
Laboratory grand opening Posted on 23 April 20183 April 2019 by Paulina Czarnecka The new SDS laboratory officially opened on 19th Aprill. It was a huge event for whole team. Guests, including brand owners, were provided a complete tour of the lab and it’s facilities along with the opportunity to attend thematical speaches. PhD Magdalena Staniszewska demonstrated inPROBE and its capabilities. Also it was good opportunity to introduce SDS Optic team by our Chief Business Officer Mateusz Sagan. Here you have some photos from event You can also watch movie from laboratory grand opening
Research Impact EU at European Parliament Posted on 20 February 20183 April 2019 by Paulina Czarnecka We had a privilege to take part in a high-level conference Research Impact EU at European Parliament in Brussels where the best R&D projects showed how their innovations changed the world around us. It was a great honor to be invited by Jerzy Buzek. This conference was a great place to how EU Research & Innovation improves everyday life in Europe. Our Chief Business Officer Mateusz Sagan joined the conference and meet with a great people over there, incl. Carlos Moedas Antonio Tajani Daria Golebiowska-Tataj Sorina Pintea. Also big applause for Krajowy Punkt Kontaktowy Programów Badawczych UE to bring so many great innovative projects from Poland for this event. Finally the Parliament has agreed to increase the budget for R&D up to €120B and focus on a life changing challenges. Sounds great and lot to be happening in Europe in the coming years
